Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2005-02-15
2005-02-15
Jones, Dwayne (Department: 1614)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C544S170000, C514S058000, C514S238800
Reexamination Certificate
active
06855820
ABSTRACT:
Disclosed is the compound (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and pharmaceutically acceptable salts and solvates thereof, methods for preparing them, pharmaceutical compositions comprising them, and processes for their preparation; also disclosed is a method of treating depression, attention deficit hyperactivity disorder (ADHD), obesity, migraine, sexual dysfunction, Parkinson's disease, Alzheimer's disease, or addiction to cocaine or nicotine-containing (especially tobacco) products using such compound, salts, solvates or compositions.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3622675 (1971-11-01), Koppe et al.
patent: 3630200 (1971-12-01), Higuchi
patent: 3819706 (1974-06-01), Mehta
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3885046 (1975-05-01), Mehta
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3960927 (1976-06-01), Metcalf et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4347176 (1982-08-01), Mehta
patent: 4347177 (1982-08-01), Phillips
patent: 4347178 (1982-08-01), Findlay et al.
patent: 4347257 (1982-08-01), Stern
patent: 4347382 (1982-08-01), Scharver
patent: 4355179 (1982-10-01), Findlay et al.
patent: 4356165 (1982-10-01), Findlay et al.
patent: 4393078 (1983-07-01), Peck
patent: 4425363 (1984-01-01), Stern
patent: 4435449 (1984-03-01), Stern
patent: 4438138 (1984-03-01), Stern
patent: 4507323 (1985-03-01), Stern
patent: 4571395 (1986-02-01), Peck
patent: 4656026 (1987-04-01), Coffman et al.
patent: 4687660 (1987-08-01), Baker et al.
patent: 4769027 (1988-09-01), Baker et al.
patent: 4798826 (1989-01-01), Peck
patent: 4835147 (1989-05-01), Roberts
patent: 4868344 (1989-09-01), Brown
patent: 4895845 (1990-01-01), Seed
patent: 4935429 (1990-06-01), Dackis et al.
patent: 4935439 (1990-06-01), Kashman et al.
patent: RE33994 (1992-07-01), Baker et al.
patent: 5217987 (1993-06-01), Berger
patent: 5358970 (1994-10-01), Ruff et al.
patent: 5399765 (1995-03-01), Gao et al.
patent: 5427798 (1995-06-01), Ludwig et al.
patent: 5447948 (1995-09-01), Seibyl et al.
patent: 5512593 (1996-04-01), Dante
patent: 5541231 (1996-07-01), Ruff et al.
patent: 5648347 (1997-07-01), Mehta et al.
patent: 5731000 (1998-03-01), Ruff et al.
patent: 5753712 (1998-05-01), Pinsker
patent: 5763493 (1998-06-01), Ruff et al.
patent: 6274579 (2001-08-01), Morgan et al.
patent: 6337328 (2002-01-01), Fang et al.
patent: 6342496 (2002-01-01), Jerussi et al.
patent: 6391875 (2002-05-01), Morgan et al.
patent: 20020052340 (2002-05-01), Jerussi et al.
patent: 20020052341 (2002-05-01), Fang et al.
patent: 977777 (1975-11-01), None
patent: 977778 (1975-11-01), None
patent: 0 118 036 (1984-09-01), None
patent: 0 170 430 (1986-02-01), None
patent: 0 171 227 (1986-02-01), None
patent: 0 467 488 (1992-01-01), None
patent: 63-91352 (1988-04-01), None
patent: 9111184 (1991-08-01), None
patent: 9218489 (1992-10-01), None
patent: 9219226 (1992-11-01), None
patent: 9321917 (1993-11-01), None
patent: 9404138 (1994-03-01), None
patent: 9420100 (1994-09-01), None
patent: 9503791 (1995-02-01), None
patent: 9522324 (1995-08-01), None
patent: 9639133 (1996-12-01), None
patent: 9729735 (1997-08-01), None
patent: 9850044 (1998-11-01), None
patent: 9937305 (1999-07-01), None
patent: 0162257 (2001-08-01), None
Golden et al., “Bupropion in Depression,” Arch. Gen Psychiatry, vol. 45, Feb. 1988.
Laizure, et al., “Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose,”Clin. Pharm. Ther.,1985 (38), pp. 586-589.
Suckow, et al., “Enantiomeric Determination of the Phenylmorpholinol Metabolite of Bupropion in Human Plasma Using Coupled Achiral-Chiral Liquid Chromatography,”Biomedical Chromatography,1997, vol. 11, pp. 174-179.
Welch, et al., “Phmaracological significance of the species difference in bupropion metabolism,”Xenobiotica,1987, vol. 17, No. 3, pp. 287-298.
Suckow, et al., “Pharmacokinetics of Bupropion and Metabolites in Plasma and Brain of Rats, Mice, and Guinea Pigs,”The American Society for Pharmacology and Experimental Therapeutics,1986, vol. 14, No. 6, pp. 692-697.
Posner, J., et al., “The Deposition of Bupropion and Its Metabolites in Healthy Male Volunteers After_and Multiple Doses,”Eur. J. Clin. Pharmacol.,1985, vol. 29, pp. 97-103.
Ascher, J.A., et al., “Bupropion: A Review of its Mechanism of Antidepressant Activity,”J. Cling. Psych.,1995, vol. 56, pp. 395-401.
Boswell, G. Evan, et al., “Synthesis and Anti-tetrabenazine Activity of C-3-e Analogues of Dimethyl-2-phenylmorpholines,”J. Heterocyclic Chem.,vol. 33, pp. 33-39, 1993.
Boswell, G. Evan, et al., “Synthesis, Stereochemistry and Anti-tetrabenazine Activity of Bicyclo Analogues_2-phenylmorpholines,”J. Heterocyclic Chem.,vol. 34, pp. 1813-1820, 1992.
Martin et al., “Antidepressant Profile of Bupropion and three Metabolites in Mice,”Pharmacopsychiatry,1990, vol. 23, pp. 187-194.
Eisman, et al., “The Isolation and Identification of Some Basic Urinary Metabolites of Bupropion-HCL in Man,”Pharmacologist,1979, vol. 21, p. 191.
Cooper et al., “Behavioral and Biochemical Effects of the Antidepressant, Bupropion (Wellbutrin): Evidence for Selective Blockade of Dopamine Uptake in Vivo,”The Journal of Pharmacology and Experimental Therapeutics,1980, vol. 215, No. 1.
Ferris et al., “Some Neurochemical Properties of a New Antidepressant, Bupropion Hydrochloride (Wellbutrin),”Drug Development Research,1981, vol. 1, pp. 21-35.
Maxwell, et al., “Bupropion,”Pharmacol&Biochem Properties Drug Substances(M E Goldberg, Ed),Am Pharm Assoc. Pub., Washington, 1981, vol. 3, pp. 1-55.
Findlay, et al., “Pharmacokinetics of Bupropion, a Novel Antidepressant Agent, Following Oral Administration to Healthy Subjects,”European Journal of Clinical Pharmacology,1981, vol. 21, pp. 127-135.
Butz, et al., “Radioimmunoassay and Pharmacokinetic Profile of Bupropion in the Dog,”The Journal of Pharmacology and Experimental Therapeutics,1981, vol. 217, No. 3.
Ferris et al., “Bupropion: A New Antidepressant Drug, The Mechanism of Action of Which is Not associated with Down-Regulation of Postsynaptic β-Adrenergic, Serotonergic (5-HT2), β2-Adrenergic, Imipramine and Dopaminergic Receptors in Brain,”Neuropharmacology,1983, vol. 22, No. 11, pp. 1257-1267.
Mehta, “The Chemistry of Bupropion,”J. Clinical Psychiatry,May 1983, 44:5 (Sec. 2).
Schroeder, David, “Metabolism and Kinetics of Bupropion,”J. Clinical Psychiatry,May 1983, 44:5 (Sec. 2).
Lai, et al., “Clinical Pharmacokinetics of Bupropion: A Reivew,”J. Clinical Psychiatry,May 1983, 44:5 (Sec. 2).
Cooper et al., “Determination of Bupropion nd Its Major Basic Metabolites in Plasma by Liquid Chromatography with Dual-Wavelength Ultraviolet Detection,”Journal of Pharmaceutical Sciences,Aug. 1984, vol. 73, No. 8.
Laizure et al., “Stability of Bupropion and its Major Metabolites in Human Plasma,”Therapeuytic Drug Monitoring,1985, vol. 7, pp. 447-450.
Cooper et al., “Bupropion: Possible Rose of Major Metabolites in Mode of Action,”Clin. Pharmacol. Ther.,Feb. 1985, vol. 37, No. 2.
DeVane, et al., “The Effect of Experimentally-Induced Renal Failure on Accumulation of Bupropion and its major basic metabolites in plasma and brain of guinea pigs,”Psychopharmacology,1986, vol. 89, pp. 404-408.
Perumal, et al., “Effect of Plasma from Patients Contianing Bupropion and its Metabolites on the Uptake of Norepinephrine,”Neuropharmacology,1986, vol. 25, No. 22, pp. 199-202.
Thomas Smith et al., “Brain regional [3H]flunitrazepam binding in rats chronically treated with bupropion or B.W.306U,”Brain Research,1986, 367, pp. 385-389.
Ferris et al., “Mechanism of Antidepressant Activity of Bupropion,”J Clin Psychiatry Monograph,1993, v
Atkins Richard
Broom Toby
Delpogetto Monica
Negus Alan
Oxley Paul William
Deppenbrock Bonnie L.
Jones Dwayne
SmithKline Beecham Corporation
LandOfFree
Pharmaceutically active morpholinol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutically active morpholinol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active morpholinol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3457617